Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19.

Jin Yeong Hong Jae-Hoon Ko Jinyoung Yang Soyoung Ha Eliel Nham Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Jin Yang Baek You Min Sohn Hyo Jung Park Beomki Lee Hee Jae Huh Eun Suk Kang Gee Young Suh Chi Ryang Chung Kyong-Ran Peck

Published in: Yonsei medical journal (2022)

A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.

Keyphrases

sars cov
immune response
rheumatoid arthritis
coronavirus disease
respiratory syndrome coronavirus
juvenile idiopathic arthritis
high dose
low dose
early onset
rheumatoid arthritis patients
risk factors
drug induced
toll like receptor
systemic lupus erythematosus